导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 23.54% | 190/4773 |
| 近一周 | -2.47% | 2276/5462 |
| 近一月 | -9.83% | 4878/5421 |
| 近一季 | -13.30% | 3980/5209 |
| 近半年 | 19.37% | 184/4920 |
| 近一年 | 28.67% | 211/4366 |
| 近两年 | 167.99% | 131/2954 |
| 近三年 | 113.99% | 87/2253 |
| 成立以来 | 57.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.34% 4104/4961 |
101.41% 95/5312 |
- - |
- - |
| 2025 | 38.92% 854/4813 |
0.52% 1827/3635 |
-0.29% 2877/4076 |
50.48% 304/4524 |
-7.89% 3850/4813 |
| 2024 | 28.53% 151/3463 |
-8.99% 2259/2808 |
0.49% 595/3014 |
17.63% 1156/3129 |
19.47% 51/3463 |
| 2023 | -6.08% 810/2656 |
13.78% 258/2280 |
-7.89% 1928/2385 |
-9.42% 1820/2515 |
-1.07% 282/2655 |
| 2022 | -37.28% 1751/2207 |
-21.05% 1598/1919 |
0.74% 1529/2016 |
-20.70% 1870/2113 |
-0.56% 1623/2208 |
| 2021 | 31.90% 61/1822 |
-7.89% 1068/1255 |
39.28% 20/1330 |
-3.03% 608/1466 |
6.03% 244/1822 |
| 2020 | - - |
- - |
- - |
-3.84% 1099/1164 |
6.70% 748/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏国证半导体芯片ETF联接A VS. 长安沪深300非周期A(740101) |